Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Argenica Advances Preparations for Late-Stage Stroke Drug Trial

AGN: $0.115 +9.52% · MC: $15M

Argenica Therapeutics is preparing a Phase 2b trial of xaranetide in patients with moderate to severe ischaemic stroke, with drug manufacturing and trial design work underway. It plans to present the trial strategy and seek US regulatory feedback before year-end. Subsequent pharmacology studies strengthened evidence that the drug acts on multiple injury pathways. The company reported cash reserves of approximately $5 million at the end of September.

Source announcements: 2026-10-30 09:10 to 2026-10-30 09:10 Sydney time
Story updated 2026-10-30 12:44 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments